结膜下地塞米松植入物实现穿透性角膜移植术后无滴眼液免疫抑制的安全性初步研究
结果显示植入物未引起眼压升高或相关不良事件,平均吸收时间6周,转为激素滴眼液过程平稳;1例术前存在角膜新生血管者发生排斥。
要点
- 结膜下地塞米松植入物在低排斥风险穿透性角膜移植术后未观察到眼压升高或植入物相关不良事件。
- 植入物平均吸收时间为6周,吸收后切换为激素滴眼液过程平稳。
- 1例术前角膜新生血管者发生排斥,属非预期方案偏离。
核心结论
- 首次证明低排斥风险穿透性角膜移植术后可实现无滴眼液免疫抑制。
主要发现
- 未观察到植入物相关的眼压升高或其他不良事件。
- 植入物平均吸收时间为6周。
- 植入物吸收后切换为激素滴眼液过程平稳。
- 1例术前存在角膜新生血管者(非预期方案偏离)发生排斥。
关键数值与推荐
- 主要结局指标为术后1个月眼压,未观察到眼压升高。
- 植入物注射位置为12点方位、距角膜缘5 mm。
- 计划在植入物完全吸收后开始激素滴眼液治疗。
- 随访监测12个月,包括眼压、不适与充血评分、植入物状态、排斥事件及光学相干断层扫描中央角膜厚度。
临床怎么用
- 对于低排斥风险穿透性角膜移植患者,术中结膜下地塞米松植入物可能作为无滴眼液免疫抑制的候选方案。
- 术后需监测植入物吸收状态,吸收完成后按计划切换为激素滴眼液。
- 术前角膜新生血管者可能不适合该方案,需谨慎评估排斥风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIM: Rejection is the main cause of graft failure after penetrating keratoplasty (PK). Its prevention by repeated instillation of steroid eye-drops has not evolved in decades. Poor adherence and discontinuous nature of eye-drop treatment may explain some PK failures. In a rabbit model, we previously demonstrated that a subconjunctival dexamethasone implant was well tolerated and prevented rejection efficiently in the first 5-6 weeks. This clinical trial investigates its tolerance and safety after PK. METHODS: Single-centre, phase II non-randomised tolerance and safety pilot study (NCT02834260). Designed to analyse the risk of elevated intraocular pressure (IOP), discomfort and resorption time. Fourteen patients with a low rejection risk indication of PK were enrolled between January 2017 and August 2018. The implant was injected in the 12 o'clock position, 5 mm from the limbus, at the end of PK. A steroid eye-drop treatment was planned when implant resorption was complete. Patients were monitored regularly for 12 months: IOP (main outcome measure at 1 month), discomfort and redness scores, implant status, rejection episode and central corneal thickness by optical coherence tomography. An independent data safety monitoring committee verified safety aspects. RESULTS: No increase in IOP or other adverse event related to the implant was observed. Average resorption time was 6 weeks. The switch to steroid eye-drops was uneventful. One patient, included despite preoperative corneal neovascularisation (unintended protocol deviation) experienced a rejection. CONCLUSIONS: This is the first proof of concept that dropless immunosuppression is possible after low rejection risk PK. TRIAL REGISTRATION NUMBER: NCT02834260.
引用
- Trone MC, Poinard S, Crouzet E, et al. Dropless penetrating keratoplasty using a subconjunctival dexamethasone implant: safety pilot study. Br J Ophthalmol. 2021. PMID: 34426402. doi:10.1136/bjophthalmol-2021-319376
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。